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A b s t r a c t
Introduction: There are still limited data on the occurrence of multiple stenotic lesions within the infarct-related artery (IRA) 
in acute myocardial infarction (MI), and there is no consensus on the optimal treatment of this patient subgroup, which varies be-
tween centers and operators. 
Aim: To analyse the clinical efficacy of percutaneous coronary intervention (PCI) strategy of culprit lesion only in patients with 
myocardial infarction.
Material and methods: Patients with acute MI with the presence of at least two significant lesions in the IRA – (1) the target 
culprit lesion which required immediate stenting (> 50–100% stenosis) and (2) a second distal critical lesion (70–90%) – were in-
cluded in the registry. Both lesions in the IRA were considered to be independent lesions requiring two separate stent platforms to 
be covered (no overlap). The decision on the treatment strategy of either complete (CR) or culprit-lesion-only (CLO) revascularization 
was at the discretion of the operator.
Results: There were altogether 95 patients enrolled in the registry, 63 (66%) in the group with CR of the IRA and 32 (34%) with 
CLO revascularization, which did not differ in terms of baseline demographics. In-hospital and long-term outcomes were similar 
between the groups. Stent thrombosis at 1 year occurred in 1.6% in CR and in 6.2% in CLO groups respectively (statistically not sig-
nificant). There were no patients from the CLO group who had a planned percutaneous coronary intervention (PCI) of the 2nd lesion 
in the IRA during 1-year observation. 
Conclusions: At 1 year the clinical outcome was similar between those with complete and CLO PCI. Complete coverage of signif-
icant lesions did not increase the risk of stent thrombosis or need for repeated revascularization in long-term observation.
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Introduction
Concomitant significant stenosis in coronary arteries 
other than the infarct-related artery (IRA) occurs in 40% 
to 60% of patients undergoing primary percutaneous 
coronary intervention (PPCI) for ST-elevation myocardial 
infarction (STEMI) both in historic and recent data [1–7]. 
Moreover, the presence of multivessel coronary artery 
disease in the STEMI setting is usually associated with 
adverse long-term outcome [1, 3, 5–8]. According to the 
current European Society of Cardiology (ESC) revascular-
ization guidelines, PCI of only culprit vessel should be 
performed in STEMI, with an exception of cardiogenic 
shock (IIa), whereas immediate PCI of all lesions during 
PPCI may only be considered in selected patients (IIb) 
[9]. Similarly, the mode of revascularization in non-ST 
elevation myocardial infarction (NSTEMI) should be de-
cided taking into account comorbidities, clinical data and 
extent of the atherosclerotic disease. There are multiple 
data from meta-analyses, randomized trials and regis-
tries which either support complete revascularization in 
acute myocardial infarction [10–14] or support a  more 
conservative guideline-recommended approach [15–18]. 
However, there are still limited data on the occurrence 
of multiple stenotic lesions within the IRA in a STEMI and 
NSTEMI setting. At the same time there is no consensus 
on the optimal treatment of this patient subgroup. The 
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strategies vary between centers but also PCI operators. 
Scarce data suggest that “spot” only coverage of stenotic 
lesions with minimization of stent length might be supe-
rior to the “full metal jacket” strategy at least in a group 
of stable angina patients [19, 20]. It was also confirmed 
that the length and number of implanted drug eluting 
stents (DES) is associated with increased risk of stent 
thrombosis [21, 22].
Aim
The aim of the CORAMI registry was to assess the 
contemporary treatment strategies in acute myocardial 
infarction patients with multiple stenotic lesions in the 
IRA with either complete (CR) or culprit-lesion-only (CLO) 
revascularization and its influence on long-term out-
come. 
Material and methods
The CORAMI Registry was first planned as a random-
ized clinical trial (NCT01218815). The study was launched 
in Polish and Slovenian sites, but due to difficulties with 
enrollment the study was terminated. The investigators 
decided that it would be worth continuing the research, 
so the CORAMI Registry was started instead. 
The CORAMI Registry was a prospective, internation-
al (Poland, Slovenia), multicenter (6 sites in Poland, 1 in 
Slovenia) observational study which was performed in 
experienced invasive cardiology centers with 24/7 PCI 
duty with patient enrollment between October 2011 and 
June 2012.
Patients with STEMI or NSTEMI over 18 years old with 
the presence of at least two significant lesions in the IRA 
– (1) the target culprit lesion which required immediate 
stenting (> 50–100% stenosis) and (2) a  second distal 
critical lesion (70–90%) – were included in the registry. 
Both lesions in the IRA were considered to be indepen-
dent lesions requiring two separate stent platforms to be 
covered (no overlap). The decision on the treatment strat-
egy of either CR or CLO revascularization was at the dis-
cretion of the PCI operator. Further pharmacological treat-
ment was according to local standards and best clinical 
practice. Patient follow-up phone calls and/or ambulatory 
visits were performed at 12 months after the enrollment.
The primary end-point of this analysis were: over-
all mortality at 1 year, confirmed stent thrombosis at 
12 months according to the Academic Research Consor-
tium (ARC) definition, repeated myocardial infarction at 
12 months, urgent target vessel revascularization (TVR) at 
12 months and planned TVR (PCI or CABG) at 12 months. 
Secondary clinical endpoints included: immediate in-hos-
pital angiographic complications (at least one or more of 
the following: distal embolisation, no-reflow, slow-flow, 
acute coronary artery occlusion, artery perforation, tam-
ponade, dissection type B and above), urgent in-hospital 
TVR (PCI and/or CABG), complete radiation dose in mGy.
The CORAMI Registry complied with the Declaration 
of Helsinki and was approved by the Bioethics Com-
mittee at the Jagiellonian University in Krakow, Poland 
(KBET/140/L/2010 of October 7th, 2010). 
Statistical analysis
Data were analyzed according to the established sta-
tistical standards. Categorical variables were presented 
with counts and as percentages and continuous variables 
as means (± standard deviation). Differences between 
groups were tested using Fisher’s exact test or Pearson’s 
c2 test for categorical variables and the Mann-Whitney 
U test for continuous variables. Values of p less than 0.05 
were considered statistically significant. Two-sided tests 
were applied. All calculations were done with JMP 9.0.0 
software by an experienced statistician.
Results
There were altogether 95 patients enrolled in the 
registry, 63 (66%) in the group with complete revascu-
larization of the IRA and 32 (34%) with CLO revascular-
ization. Baseline demographics and procedural aspects 
are presented in Table I. The balance of STEMI diagnosis 
was similar between the groups (CR vs. CLO 73% vs. 84%, 
p = 0.305). In-hospital and long-term outcome as well 
as adherence to dual antiplatelet therapy are presented 
in Table II. There were no patients from the CLO group 
who had a planned PCI of the 2nd lesion in the IRA during 
1-year observation. 
Discussion
The CORAMI Registry is one of the first studies sched-
uled to evaluate the impact of complete infarct artery 
revascularization in patients who are treated with cor-
onary angioplasty with stenting during the acute phase 
of STEMI and NSTEMI. The incidence of two independent 
stenotic lesions in the IRA is a rare situation (3% in our 
population, data not shown) but certainly requires scien-
tific evaluation as there are no clear guidelines on how to 
intervene, especially in a myocardial infarction setting [9]. 
Therefore, these decisions are often based on coronary 
anatomy, patient clinical status and empirical experience 
of a single PCI operator including thrombolysis in myo-
cardial infarction (TIMI) flow after initial lesion stenting, 
presence of hemodynamic compromise, location of the 
distal lesion as well as artery diameter. In the CORAMI 
study patients with two lesions identified in the IRA were 
analyzed. The first lesion was treated as the culprit one, 
which was always stented, and the other was treated 
with a stent based on the discretion of the PCI operator 
but had to be less than 90% in diameter stenosis (we did 
not want to include patients with obvious flow limiting 
critical lesions > 90%, which should be stented during 
the index procedure). Our early assumption that most 
such patients will receive multiple stents to cover all le-
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sions turned out to be at least exaggerated. In as many 
as 34% of STEMI and NSTEMI cases the second distal 
lesion in the IRA was left without stenting and intended 
for conservative treatment. During a 12-month follow-up 
none of the 2nd lesions in the CLO group were scheduled 
for an elective PCI. Elective PCIs of non-target vessel le-
sions were performed equally between study groups in 
follow-up since ca. 2/3 of study patients had multivessel 
disease diagnosed in baseline angiography.
The benefit of the CLO strategy in STEMI and NSTEMI 
during in-hospital stay was observed for decreased over-
all PCI time and lower radiation exposure for the patient, 
but was only borderline in terms of statistical inference. 
Even though the mean length of the implanted scaffold 
in the CR group was ca. 41 mm vs. 21 mm, the immediate 
PCI outcome in both groups was similar (a rate of TIMI 3 
flow). Periprocedural complications as defined by the 
protocol were rare in both groups. Both during in-hospi-
tal and 12-month observation the occurrence of death, 
stent thrombosis and urgent TVR was more frequently 
observed in the CLO group, but due to low sample size 
it was not statistically significant. Thus we need to con-
clude that in the CORAMI patient sample there was no 
benefit from complete IRA revascularization at least in 
terms of occurrence of clinical endpoints in longer obser-
vation. Contrary to some reports, there was no excess of 
stent thrombosis with more stents implanted [21, 22]. It 
is also interesting to observe that as many as half of pa-
tients in the CORAMI registry did not take dual antiplate-
Table I. Baseline characteristics, angiography 
and PCI 
Variable CR CLO Value of p
No. of patients 66% (63) 34% (32) –
Age 66.3 ±11.3 69.7 ±11.9 0.182
Gender (male) 75% (47) 75% (25) 0.966
BMI [kg/m2] 27.5 ±3.4 27.1 ±3.1 0.518
Previous myocardial 
infarction
11% (7) 9% (3) 0.794
Arterial hypertension 63.5% (40) 62.5% (20) 0.912
Hyperlipidemia 40% (25) 31% (10) 0.546
Diabetes mellitus 16% (10) 12.5% (4) 0.767
Chronic kidney disease 3% (2) 3% (1) 0.989
Previous stroke 1.6% (1) 0% (0) 0.473
Previous PCI 6% (4) 3% (1) 0.613
Previous CABG 1.6% (1) 0% (0) 0.473
Smoking 59% (37) 37.5% (12) 0.262
Clinical status on admission:
HR 77.3 ±19.5 75.8 ±13.6 0.971
SBP 141 ±26 131 ±21 0.075
DBP 81 ±17 76 ±11 0.042
Number of critically stenosed arteries:
1-vessel disease (IRA 
only)
35% (22) 31% (10) 0.820
Multivessel disease 65% (41) 69% (22)  
Infarct-related artery (IRA):
LAD 25% (16) 41% (13) 0.269
Cx 8% (5) 9% (3)
RCA 67% (42) 50% (16)
TIMI before PCI:
0 41% (26) 56% (18) 0.407 
1 14% (9) 16% (5)  
2 21% (13) 9% (3)  
3 24% (15) 19% (6)
Number of stents in IRA:
≥ 2 stents in IRA 100% (63) 0% (0) < 0.001 
1 stent in IRA 0% (0) 100% (32)  
No stents in IRA 0% (0) 0% (0)
Type of stent:
DES 44% (28) 34% (11) 0.385 
PCI procedure time [min] 33.0 ±21.7 26.6 ±18.1 0.092
Radiation [mGy] 1406 ±921 1171 ±1250 0.055
LVEF (%) 53.2 ±10.9 51.5 ±12.3 0.566
1st stent diameter [mm] 3.2 ±0.4 3.2 ±0.4 0.824
1st stent length [mm] 20.5 ±7.3 21.1 ±7.4 0.737
2nd stent diameter [mm] 3.2 ±0.5 – –
2nd stent length [mm] 20.2 ±7.9 – –
TIMI 3 flow after PCI 95% (60) 91% (29) 0.401
Thrombectomy 25% (16) 37.5% (12) 0.242
Table II. Primary and secondary clinical endpo-
ints and adherence to DAPT 
Variable CR CLO Value of p
No. of patients 66% (63) 34% (32) –
12 months observation:
Death 6.4% (4) 9.4% (3) 0.593
Stent thrombosis 1.6% (1) 6.2% (2) 0.219
Acute MI 1.6% (1) 3.1% (1) 0.622
Urgent TVR 4.8% (3) 9.4% (3) 0.383
Planned TVR 0% (0) 0% (0) –
In-hospital events:
Death 1.6% (1) 6.2% (2) 0.219
Stent thrombosis 1.6% (1) 6.2% (2) 0.219
Angiographic  
complications*
1.6% (1) 3.1% (1) 0.622
Urgent TVR (PCI or CABG) 1.6% (1) 6.2% (2) 0.219
DAPT at 12 months:
Clopidogrel 47.6% (30) 34% (11) 0.452
Prasugrel 1.6% (1) 6.2% (2)
Ticagrelor 4.8% (3) 6.2% (2)
ASA only 46% (29) 53.6% (17)
*Defined as at least one or more of the following: distal embolisation, no-re-
flow, slow-flow, acute coronary artery occlusion, artery perforation, tamponade, 
dissection type B and above. DAPT – dual antiplatelet therapy, ASA – acetylsal-
icylic acid, TVR – target vessel revascularization, PCI – percutaneous coronary 
intervention, CABG – coronary artery bypass graft, MI – myocardial infarction.
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let therapy any longer at 12 months. The CORAMI study 
raises a number of issues that would ideally be answered 
in a larger randomized study. 
This was a registry study with low sample size, and 
drawing definite conclusions based on the results of 
CORAMI should be cautious. There was no independent 
angiographic core lab evaluation of PCI procedures and 
procedural complications. The follow-up observation was 
mainly performed by telephone calls. In addition, the 
results cannot be applied to patients treated with new 
stents designs (i.e. mesh covered stents, self-expandable 
stents) or bioresorbable vascular scaffold implantation 
during primary PCI for STEMI [23, 24].
Conclusions
Complete infarct-related artery revascularization in 
acute myocardial infarction was performed in two-thirds 
of patients in the CORAMI Registry. At 1 year the clinical 
outcome was similar between those with complete and 
CLO PCI. Complete coverage of significant lesions did not 
increase the risk of stent thrombosis or need for repeat-
ed revascularization in long-term observation. 
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